Disease activity and cytokine production in mitogen-stimulated peripheral blood mononuclear cells from patients with rheumatoid arthritis

Medical Principles and Practice

Volumn 19, Issue 1, 2009, Pages 33-39

  Uppal, Sukhbir S ^a,b   Raghupathy, Raj ^a   Hayat, Sawsan J ^b   Longenecker, Joseph C ^a   Abraham, Mini ^a   Rawoot, Parvez ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MUBARAK AL KABEER HOSPITAL   (Kuwait)

Author keywords

Arthritis; Cytokines; Interferon ; Peripheral blood mononuclear cells; Rheumatoid arthritis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 8; LYMPHOTOXIN; MITOGENIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73849095424     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000252832     Document Type: Article

References (35)

1. Arend WP: Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 2001; 30: 1-6.
2. Arnett FC, Edworthy SM, Bloch DA, Mc-Shane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
3. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
4. Fransen J, Creemers MC, van Riel PL: Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-1255.
5. Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-1315.
6. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-346.
7. Arend WP: Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001; 45: 101-106.
8. Kusaba M, Honda J, Fukuda T, Oizumi K: Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis. J Rheumatol 1998; 25: 1466-1471.
9. Haddad A, Bienvenu J, Miossec P: Increased production of a Th2 cytokine profile by activated whole blood cells from rheumatoid arthritis patients. J Clin Immunol 1998; 18: 399-403.
10. Canete JD, Martinez SE, Farres J Sanmarti R, Blay M, Gomez A, Salvador G, Munoz-Gomez J: Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000; 59: 263-268.
11. Loubet-Lescoulie P, Constantin A, Mazieres B, Tkaczuk J, de Préval C, Cantagrel A: Decreased peripheral blood T cell cytokine gene expression in rheumatoid arthritis. Scand J Rheumatol 1999; 28: 244-251.
12. Reuter A, Bernier J, Vrindts-Gevaert Y, Meuleman-Gathy R, Malaise M, Fiers W, Franchimont P: Production of interferon gamma by peripheral blood mononuclear cells from normal subjects and from patients with rheumatoid arthritis. Clin Exp Rheumatol 1988; 6: 347-354.
13. Forrest CM, Harman G, McMillan RB, Stoy N, Stone TW, Darlington LG: Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 89-92.
14. Rodenburg RJ, van den Hoogen FH, van de Putte LB, van Venrooij WJ: Peripheral blood monocytes of rheumatoid arthritis patients do not express elevated TNF alpha, IL-1- , and IL-8 mRNA levels. A comparison of monocyte isolation procedures. J Immunol Methods 1998; 221: 169-175.
15. Raghav SK, Gupta B, Agrawal C, Chaturvedi VP, Das HR: Expression of TNF-alpha and related signaling molecules in the peripheral blood mononuclear cells of rheumatoid arthritis patients. Mediators Inflamm 2006; 2006: 12682.
16. Petrovic-Rackov L: Evaluation of the degree of clinical rheumatoid arthritis activity based on the concentrations of cytokines TNF-alpha, IL-12, IL-15, and IL-18 in serum and synovial fluid (in Serbian). Vojnosanit Pregl 2006; 63: 21-26.
17. Firestein GS: Etiology and pathogenesis of rheumatoid arthritis; in Harris ED Jr, Budd RC, Genovese MC, Firestein GS, Sargent JS, Sledge CB (eds): Kelley's Textbook of Rheumatology, ed 7. Philadelphia, Elsevier Saunders, 2005, pp 1013-1042.
18. Steiner G, Tohidast-Akrad M, Witzmann G Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen JS: Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 202-213.
19. Robak T, Gladalska A, Stepien H: The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998; 9: 145-154.
20. Tanabe M, Ochi T, Tomita T,Suzuki R, Sakata T, Shimaoka Y, Nakagawa S, Ono, K: Remarkable elevation of interleukin 6 and interleukin levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol 1994; 21: 830-835.
21. Sivalingam SP, Yoon KH, Koh DR, Fong KY: Single-nucleotide polymorphisms of the interleukin-gene promoter region in rheumatoid arthritis patients: Protective effect of AA genotype. Tissue Antigens 2003; 62: 498-504.
22. Toh ML, Miossec P: The role of T cells in rheumatoid arthritis: New subsets and new targets. Curr Opin Rheumatol 2007; 19: 284-288.
23. Kehlen A, Thiele K, Riemann D, Langner J: Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol 2002; 127: 539-546.
24. Ryu S, Lee JH, Kim SI: IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006; 25: 16-20.
25. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Kimczak E, Chwalinska-Sadowska H, Maslinski W: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164: 2832-2838.
26. Mosaad YM, Metwally SS, Auf FA, Abdel-Samee ER, el-Deek B, Limon NI, el-Chennawi FA: Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: Relation with disease activity and autoantibodies production. Egypt J Immunol 2003; 10: 19-26.
27. Sato M, Takemura M, Shinohe R, Koishi H, Morita T, Seishima M: Clinical significance of serum IL-18 determination in rheumatoid arthritis (in Japanse). Rinsho Byori 2004; 52: 109-114.
28. van Roon JA, Verhoef CM, van Roy JL, Gmelig-Meyling FH, Huber-Bruning O, Lafeber FP, Bijlsma JW: Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann Rheum Dis 1997; 56: 656-660.
29. Huang JL, Kuo ML, Hung IJ, Wu CJ, Ou LH, Cheng JH: Lowered IL-4-producing T cells and decreased IL-4 secretion in peripheral blood from subjects with juvenile rheumatoid arthritis. Chang Gung Med J 2001; 24: 77-83.
30. Keystone E, Wherry J, Grint P: IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 629-639.
31. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P: Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42: 963-970.
32. Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F: High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: Association with dendritic cell growth activity. J Rheumatol 2002; 29: 454-461.
33. Benucci M, Li Gobbi F, Fossi F, Cammelli E, Manfredi M: Peripheral mononuclear cells and cytokine circulating levels during adalimumab therapy in patients with rheumatoid arthritis (in Italian). Recenti Prog Med 2005; 96: 424-427.
34. Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O: Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004; 63: 681-687.
35. Schotte H, Schluter B, Willeke P, Mickholz E, Schorat MA, Domschke W, Gaubitz M: Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 960-964.